Yahoo
BSE - Delayed Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)

1,778.25 +15.30 (+0.87%)
At close: October 30 at 3:57:45 PM GMT+5:30
SUNPHARMA.BO Q2 2027 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for SUNPHARMA.BO
  • Previous Close 1,762.95
  • Open 1,762.95
  • Bid 1,778.25 x --
  • Ask 1,778.25 x --
  • Day's Range 1,762.95 - 1,854.80
  • 52 Week Range 1,547.25 - 1,854.80
  • Volume 243,357
  • Avg. Volume 127,909
  • Market Cap (intraday) 4.267T
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) 39.08
  • EPS (TTM) 45.50
  • Earnings Date (est.) Jan 28, 2027
  • Forward Dividend & Yield 16.50 (0.97%)
  • Ex-Dividend Date Feb 5, 2026
  • 1y Target Est 1,963.26

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

sunpharma.com

43,000

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 155.21B
Earnings 33.69B
Profit Margin 21.71%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50B
100B
150B
17.0%
18.0%
19.0%
20.0%
21.0%

Analyst Insights

View More

Analyst Price Targets

1,550.00 Low
1,963.26 Average
1,778.25 Current
2,450.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.21%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    568.09B

  • Net Income Avi to Common (ttm)

    109.15B

  • Diluted EPS (ttm)

    45.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    278.8B

  • Total Debt/Equity (mrq)

    6.68%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: